Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®
-
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
-
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
-
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
-
BioStem Technologies to Sponsor MRO Better Half Dash
-
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
-
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
-
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
-
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts